Skip to main content

Table 3 Multivariate analysis results for response rate (RR) and progression-free survival (PFS)

From: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

 

Metastases

AKT Positive

AKT negative

MAPK Positive

MAPK Negative

Response Rate (%)

9%

58%

10%

47%

Multivariate OR (95%CI)

0.13 (0.018–0.9)

0.26 (0.03–1.95)

Logistic regression p value

0.04

0.9

Median PFS (months)

2.3

9.2

2.3

8.6

Multivariate HR (95%CI)

0.63 (0.42–0.86)

0.49 (0.28–0.95)

Cox regression p value

0.0007

0.002

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us